Cargando…

Fe-HBED Analogs: A Promising Class of Iron-Chelate Contrast Agents for Magnetic Resonance Imaging

Contrast-enhanced magnetic resonance imaging is an essential tool for disease diagnosis and management; all marketed clinical magnetic resonance imaging (MRI) contrast agents (CAs) are gadolinium (Gd) chelates and most are extracellular fluid (ECF) agents. After intravenous injection, these agents r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bales, Brian C., Grimmond, Brian, Johnson, Bruce F., Luttrell, M. Todd, Meyer, Dan E., Polyanskaya, Tatyana, Rishel, Michael J., Roberts, Jeannette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961518/ https://www.ncbi.nlm.nih.gov/pubmed/31969797 http://dx.doi.org/10.1155/2019/8356931

Ejemplares similares

Safety and efficacy of a novel iron chelator (HBED; (N,N′‐Di(2‐hydroxybenzyl)ethylenediamine‐N,N′‐diacetic acid)) in equine (Equus caballus) as a model for black rhinoceros (Diceros bicornis)
por: Sullivan, Kathleen E., et al.
Publicado: (2022)

(68)Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients
por: Sathekge, Mike, et al.
Publicado: (2016)

Performance of Redox Active and Chelatable Iron Assays to Determine Labile Iron Release From Intravenous Iron Formulations
por: Pai, AB, et al.
Publicado: (2017)

Fe(iv) alkylidenes via protonation of Fe(ii) vinyl chelates and a comparative Mössbauer spectroscopic study
por: Lindley, Brian M., et al.
Publicado: (2015)

Repeatability of (68)Ga-PSMA-HBED-CC PET/CT–Derived Total Molecular Tumor Volume
por: Seifert, Robert, et al.
Publicado: (2022)

(68)Ga-HBED-CC-WL-12 PET in Diagnosing and Differentiating Pancreatic Cancers in Murine Models
por: Xiang, Qiying, et al.
Publicado: (2023)

Chemical Stability of the Fertilizer Chelates Fe-EDDHA and Fe-EDDHSA over Time
por: Klem-Marciniak, Ewelina, et al.
Publicado: (2021)

Structure-Activity Relationships of Novel Salicylaldehyde Isonicotinoyl Hydrazone (SIH) Analogs: Iron Chelation, Anti-Oxidant and Cytotoxic Properties
por: Potůčková, Eliška, et al.
Publicado: (2014)

An ultra-sensitive T(2)-weighted MR contrast agent based on Gd(3+) ion chelated Fe(3)O(4) nanoparticles
por: Chen, Jing, et al.
Publicado: (2020)

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer
por: Afshar-Oromieh, Ali, et al.
Publicado: (2014)

Synthesis of an Al(18)F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand in an automated synthesis platform
por: Giglio, Javier, et al.
Publicado: (2018)

Synthesis of novel technetium-99m tricarbonyl-HBED-CC complexes and structural prediction in solution by density functional theory calculation
por: Shi, Shengyu, et al.
Publicado: (2019)

Ga-68 Prostate-Specific Membrane Antigen-HBED-CC Positron Emission Tomography/Computed Tomography in Anaplastic Thyroid Carcinoma
por: Subudhi, T. Kishan, et al.
Publicado: (2022)

Iron Chelators in Treatment of Iron Overload
por: Entezari, Sarina, et al.
Publicado: (2022)

Defining the conditions for the development of the emerging class of Fe(III)-based MRI contrast agents
por: Baranyai, Zsolt, et al.
Publicado: (2021)

Iron chelation and multiple sclerosis
por: Weigel, Kelsey J., et al.
Publicado: (2014)

Iron Chelation in Local Infection
por: Scott, Cassidy, et al.
Publicado: (2021)

Role of Iron Chelators in Mucormycosis
por: Mahalmani, Vidya, et al.
Publicado: (2021)

Conservative Iron Chelation for Neuroferritinopathy
por: Marchand, Felix, et al.
Publicado: (2022)

Novel Preclinical and Radiopharmaceutical Aspects of [(68)Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer
por: Eder, Matthias, et al.
Publicado: (2014)

(68)Ga-HBED-CC-PSMA PET/CT Versus Histopathology in Primary Localized Prostate Cancer: A Voxel-Wise Comparison
por: Zamboglou, Constantinos, et al.
Publicado: (2016)

Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients
por: Afshar-Oromieh, Ali, et al.
Publicado: (2017)

Aggregation of Mutant Cysteine String Protein-α via Fe-S Cluster-Binding is mitigated by Fe-chelators
por: Naseri, Nima N., et al.
Publicado: (2020)

Bismuth chelate as a contrast agent for X-ray computed tomography
por: Fu, Ji-jun, et al.
Publicado: (2020)

Effects of mineral methionine hydroxy analog chelate in sow diets on epigenetic modification and growth of progeny
por: Jang, Ki Beom, et al.
Publicado: (2020)

Promising Performance of 4HMS, a New Zirconium-89 Octadendate Chelator
por: Alnahwi, Aiman H., et al.
Publicado: (2020)

Metal Complexes or Chelators with ROS Regulation Capacity: Promising Candidates for Cancer Treatment
por: Li, Xiang, et al.
Publicado: (2021)

Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
por: Dietlein, Markus, et al.
Publicado: (2015)

Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with (68)Ga-PSMA-HBED-CC PET-positive prostate cancer lesions
por: Meißner, Sebastian, et al.
Publicado: (2017)

Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer
por: Jilg, Cordula A., et al.
Publicado: (2017)

Early transcriptomic response to Fe supply in Fe-deficient tomato plants is strongly influenced by the nature of the chelating agent
por: Zamboni, Anita, et al.
Publicado: (2016)

Objectives and Methods of Iron Chelation Therapy
por: Hershko, C., et al.
Publicado: (2003)

Iron Chelation Therapy in Thalassemia Syndromes
por: Cianciulli, Paolo
Publicado: (2009)

Iron Chelation Therapy in Myelodysplastic Syndromes
por: Messa, Emanuela, et al.
Publicado: (2010)

Myelodysplastic Syndromes and Iron Chelation Therapy
por: Angelucci, Emanuele, et al.
Publicado: (2017)

Iron chelation in treatment of superficial siderosis
por: Derle, Eda
Publicado: (2018)

Reversing oncogenic transformation with iron chelation
por: Abdelaal, Gina, et al.
Publicado: (2021)

Emerging Roles of the Iron Chelators in Inflammation
por: Di Paola, Alessandra, et al.
Publicado: (2022)

Combination of Fe/Cu –chelators and docosahexaenoic acid: an exploration for the treatment of colorectal cancer
por: Yu, Nanhui, et al.
Publicado: (2017)

Iron(iii) chelated paramagnetic polymeric nanoparticle formulation as a next-generation T(1)-weighted MRI contrast agent
por: Marasini, Ramesh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jd3k40o95htep6sllpvsjoj7vf